Anixa biosciences stock.

The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of …Dec 1, 2023 · See the latest Anixa Biosciences Inc stock price (ANIX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.The following insiders have purchased ANIX shares in the last 24 months: Amit Kumar ($69,540.00), Lewis H Titterton Jr ($155,021.44), and Michael Catelani ($26,367.77). How much insider buying is happening at Anixa Biosciences? Insiders have purchased a total of 71,253 ANIX shares in the last 24 months for a total of $250,929.21 bought.

Currently, the analyst consensus on Anixa Biosciences is a Moderate Buy with an average price target of $9.50. See the top stocks recommended by analysts >> The company has a one-year high of $6. ...

The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.

SAN JOSE, Calif., Nov. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...Oct 13, 2023 · The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. In depth view into ANIX (Anixa Biosciences) stock including the latest price, news, dividend history, earnings information and financials.Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. Anixa Biosciences, Inc. Common Stock (ANIX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Anixa Biosciences, Inc. 3150 Almaden Expressway. Suite 250 San Jose, CA 95118 408-708-9808 [email protected]

Analyst Recommendations on Copytele Inc. HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating. Mar. 23. MT. Chardan Adjusts Price Target on Anixa Biosciences to $9 From $8, Keeps Buy Rating. Mar. 22. MT. Chardan Initiates Anixa Biosciences With Buy Rating, $8 Price Target. Dec. 23.

Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get ...The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity ; Anixa Biosciences is estimated to be 41% undervalued based on current share price of US$4.25 ; When compared to theindustry average discount to fair value of 32%, Anixa Biosciences' competitors seem to be trading at a lesser discountSAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...Anixa Biosciences, Inc. Common Stock (ANIX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 - 3, 2023.

Is ANIXA BIOSCIENCES INC (ANIX) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. ANIXA BIOSCIENCES INC is a member of the Medical sector.SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of …Anixa Biosciences Inc. Watch list NEW Set a price target alert Closed Last Updated: Nov 24, 2023 12:59 p.m. EST Delayed quote $ 2.9600 0.1000 3.50% Previous Close $2.8600 Advanced Charting... 22 Mar 2021 ... Anixa Biosciences, Inc. is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.Overview. Anixa is a biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutics portfolio consists of a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. Anixa’s vaccine portfolio consists of technology focused on the immunization ...Anixa Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | BOERSE MUENCHEN: CY71 | BOERSE MUENCHENAug 31, 2022 · SAN JOSE, Calif., Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...

Anixa Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Anixa ...

See the latest Anixa Biosciences Inc stock price (ANIX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic ...Barcus covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, uniQure, and Purple Biotech. According to TipRanks , Barcus has an average return of -0.9% and a 37.50% success ...Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the ...Oct 3, 2023 · SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ... SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 - 3, 2023. The presentation, entitled 'Infusion of Autologous T Cells …Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit. IMPACT. SENTIMENT. 08/10/2023 09:30 AM. ANIX : Nasdaq.

Nov 20, 2023 · Anixa Biosciences Inc’s trailing 12-month revenue is $0.2 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.320 per share for the current fiscal year. Anixa Biosciences Inc does not currently pay a dividend.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the formation of its Breast Cancer ...

SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual …SAN JOSE, Calif., Aug. 23, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced ...In a report released today, Matthew Barcus from Chardan Capital reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $9.00.The company’s shares closed ...13 Mar 2023 ... About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's ...Jun 22, 2023 · ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its …Zacks Equity Research. Anixa Biosciences, Inc. ANIX was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares ...Sep 21, 2023 · ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA SecuritiesDec 8, 2022 · SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ... Anixa Biosciences, Inc. Common Stock (ANIX) Stock Price, Quote, News & History | Nasdaq Created with Sketch. Market Activity Funds + ETFs P/E & PEG Ratios when …Instagram:https://instagram. financial planner knoxville tngood place to buy silverallk stock forecaststock cmg Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors amt stocksepirus stock Nov 17, 2023 · Stock analysis for Anixa Biosciences Inc (ANIX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. plug stock news SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...Analyst Recommendations on Copytele Inc. HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating. Mar. 23. MT. Chardan Adjusts Price Target on Anixa Biosciences to $9 From $8, Keeps Buy Rating. Mar. 22. MT. Chardan Initiates Anixa Biosciences With Buy Rating, $8 Price Target. Dec. 23.According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $11.0 with a high of $12.00 and a low of $9.00.